CRP and myocardial infarction: In a recently completed randomized placebo-controlled trial in 10,061 participants with a previous myocardial infarction and C-reactive protein concentrations ≥2 mg/L, canakinumab, a monoclonal antibody targeting IL-1beta, significantly reduced the primary end-point of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death after a median follow-up of 3.7 years.